Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients
Identifieur interne : 000428 ( Pmc/Curation ); précédent : 000427; suivant : 000429Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients
Auteurs : C. Brefel [France] ; C. Thalamas [France] ; S. Rayet [France] ; A. Lopez-Gil ; K. Fitzpatrick ; S. Bullman [Royaume-Uni] ; D R Citerone [Royaume-Uni] ; A C Taylor [Royaume-Uni] ; J L Montastruc [France] ; O. Rascol [France]Source :
- British Journal of Clinical Pharmacology [ 0306-5251 ] ; 1998.
Abstract
Ropinirole is a specific non-ergoline dopamine D2-receptor agonist with antiparkinsonian properties. The pharmacokinetic parameters of ropinirole taken in the fasted condition were compared with those when it was co-administered with food.
This was an open, randomized, two sessions cross over study in 12 patients with Parkinson’s disease, comparing the steady-state pharmacokinetic profiles of ropinirole on two different study days: ‘fasted’ and ‘fed’.
The mean
Food decreases the rate of absorption of ropinirole, but has little effect on the extent of absorption.
Url:
DOI: 10.1046/j.1365-2125.1998.t01-1-00704.x
PubMed: 9578193
PubMed Central: 1873962
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000431
Links to Exploration step
PMC:1873962Curation
No country items
A. Lopez-Gil<affiliation><nlm:aff id="au3"><institution>Clinical Pharmacology Unit, SmithKline Beecham Pharmaceuticals</institution><addr-line>Harlow, Essex, CM19 5AW UK</addr-line></nlm:aff><wicri:noCountry code="subfield">CM19 5AW UK</wicri:noCountry></affiliation><affiliation><nlm:aff id="au3"><institution>Clinical Pharmacology Unit, SmithKline Beecham Pharmaceuticals</institution><addr-line>Harlow, Essex, CM19 5AW UK</addr-line></nlm:aff><wicri:noCountry code="subfield">CM19 5AW UK</wicri:noCountry></affiliation>Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients</title><author><name sortKey="Brefel, C" sort="Brefel, C" uniqKey="Brefel C" first="C" last="Brefel">C. Brefel</name><affiliation wicri:level="1"><nlm:aff id="au1"><institution>Service de Pharmacologie Médicale et Clinique, INSERM U 455 et U 317, Faculté de Medecine</institution><addr-line>37 allées Jules Guesde, 31073 Toulouse Cedex, France</addr-line></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>37 allées Jules Guesde, 31073 Toulouse Cedex</wicri:regionArea></affiliation></author><author><name sortKey="Thalamas, C" sort="Thalamas, C" uniqKey="Thalamas C" first="C" last="Thalamas">C. Thalamas</name><affiliation wicri:level="1"><nlm:aff id="au2"><institution>Centre d’Investigation Clinique, hôpital Purpan</institution><addr-line>place du Docteur Baylac, 31059 Toulouse Cedex, France</addr-line></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>place du Docteur Baylac, 31059 Toulouse Cedex</wicri:regionArea></affiliation></author><author><name sortKey="Rayet, S" sort="Rayet, S" uniqKey="Rayet S" first="S" last="Rayet">S. Rayet</name><affiliation wicri:level="1"><nlm:aff id="au2"><institution>Centre d’Investigation Clinique, hôpital Purpan</institution><addr-line>place du Docteur Baylac, 31059 Toulouse Cedex, France</addr-line></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>place du Docteur Baylac, 31059 Toulouse Cedex</wicri:regionArea></affiliation></author><author><name sortKey="Lopez Gil, A" sort="Lopez Gil, A" uniqKey="Lopez Gil A" first="A" last="Lopez-Gil">A. Lopez-Gil</name><affiliation><nlm:aff id="au3"><institution>Clinical Pharmacology Unit, SmithKline Beecham Pharmaceuticals</institution><addr-line>Harlow, Essex, CM19 5AW UK</addr-line></nlm:aff><wicri:noCountry code="subfield">CM19 5AW UK</wicri:noCountry></affiliation></author><author><name sortKey="Fitzpatrick, K" sort="Fitzpatrick, K" uniqKey="Fitzpatrick K" first="K" last="Fitzpatrick">K. Fitzpatrick</name><affiliation><nlm:aff id="au3"><institution>Clinical Pharmacology Unit, SmithKline Beecham Pharmaceuticals</institution><addr-line>Harlow, Essex, CM19 5AW UK</addr-line></nlm:aff><wicri:noCountry code="subfield">CM19 5AW UK</wicri:noCountry></affiliation></author><author><name sortKey="Bullman, S" sort="Bullman, S" uniqKey="Bullman S" first="S" last="Bullman">S. Bullman</name><affiliation wicri:level="1"><nlm:aff id="au4"><institution>Drug Metabolism and Pharmacokinetics, SmithKline Beecham Pharmaceuticals</institution><addr-line>The Frythe, Welwyn, Herts, AL6 9AR, UK</addr-line></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>The Frythe, Welwyn, Herts, AL6 9AR</wicri:regionArea></affiliation></author><author><name sortKey="Citerone, D R" sort="Citerone, D R" uniqKey="Citerone D" first="D R" last="Citerone">D R Citerone</name><affiliation wicri:level="1"><nlm:aff id="au4"><institution>Drug Metabolism and Pharmacokinetics, SmithKline Beecham Pharmaceuticals</institution><addr-line>The Frythe, Welwyn, Herts, AL6 9AR, UK</addr-line></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>The Frythe, Welwyn, Herts, AL6 9AR</wicri:regionArea></affiliation></author><author><name sortKey="Taylor, A C" sort="Taylor, A C" uniqKey="Taylor A" first="A C" last="Taylor">A C Taylor</name><affiliation wicri:level="1"><nlm:aff id="au4"><institution>Drug Metabolism and Pharmacokinetics, SmithKline Beecham Pharmaceuticals</institution><addr-line>The Frythe, Welwyn, Herts, AL6 9AR, UK</addr-line></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>The Frythe, Welwyn, Herts, AL6 9AR</wicri:regionArea></affiliation></author><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J L" last="Montastruc">J L Montastruc</name><affiliation wicri:level="1"><nlm:aff id="au1"><institution>Service de Pharmacologie Médicale et Clinique, INSERM U 455 et U 317, Faculté de Medecine</institution><addr-line>37 allées Jules Guesde, 31073 Toulouse Cedex, France</addr-line></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>37 allées Jules Guesde, 31073 Toulouse Cedex</wicri:regionArea></affiliation></author><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name><affiliation wicri:level="1"><nlm:aff id="au1"><institution>Service de Pharmacologie Médicale et Clinique, INSERM U 455 et U 317, Faculté de Medecine</institution><addr-line>37 allées Jules Guesde, 31073 Toulouse Cedex, France</addr-line></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>37 allées Jules Guesde, 31073 Toulouse Cedex</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="au2"><institution>Centre d’Investigation Clinique, hôpital Purpan</institution><addr-line>place du Docteur Baylac, 31059 Toulouse Cedex, France</addr-line></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>place du Docteur Baylac, 31059 Toulouse Cedex</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">9578193</idno><idno type="pmc">1873962</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1873962</idno><idno type="RBID">PMC:1873962</idno><idno type="doi">10.1046/j.1365-2125.1998.t01-1-00704.x</idno><date when="1998">1998</date><idno type="wicri:Area/Pmc/Corpus">000431</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000431</idno><idno type="wicri:Area/Pmc/Curation">000428</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000428</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients</title><author><name sortKey="Brefel, C" sort="Brefel, C" uniqKey="Brefel C" first="C" last="Brefel">C. Brefel</name><affiliation wicri:level="1"><nlm:aff id="au1"><institution>Service de Pharmacologie Médicale et Clinique, INSERM U 455 et U 317, Faculté de Medecine</institution><addr-line>37 allées Jules Guesde, 31073 Toulouse Cedex, France</addr-line></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>37 allées Jules Guesde, 31073 Toulouse Cedex</wicri:regionArea></affiliation></author><author><name sortKey="Thalamas, C" sort="Thalamas, C" uniqKey="Thalamas C" first="C" last="Thalamas">C. Thalamas</name><affiliation wicri:level="1"><nlm:aff id="au2"><institution>Centre d’Investigation Clinique, hôpital Purpan</institution><addr-line>place du Docteur Baylac, 31059 Toulouse Cedex, France</addr-line></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>place du Docteur Baylac, 31059 Toulouse Cedex</wicri:regionArea></affiliation></author><author><name sortKey="Rayet, S" sort="Rayet, S" uniqKey="Rayet S" first="S" last="Rayet">S. Rayet</name><affiliation wicri:level="1"><nlm:aff id="au2"><institution>Centre d’Investigation Clinique, hôpital Purpan</institution><addr-line>place du Docteur Baylac, 31059 Toulouse Cedex, France</addr-line></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>place du Docteur Baylac, 31059 Toulouse Cedex</wicri:regionArea></affiliation></author><author><name sortKey="Lopez Gil, A" sort="Lopez Gil, A" uniqKey="Lopez Gil A" first="A" last="Lopez-Gil">A. Lopez-Gil</name><affiliation><nlm:aff id="au3"><institution>Clinical Pharmacology Unit, SmithKline Beecham Pharmaceuticals</institution><addr-line>Harlow, Essex, CM19 5AW UK</addr-line></nlm:aff><wicri:noCountry code="subfield">CM19 5AW UK</wicri:noCountry></affiliation></author><author><name sortKey="Fitzpatrick, K" sort="Fitzpatrick, K" uniqKey="Fitzpatrick K" first="K" last="Fitzpatrick">K. Fitzpatrick</name><affiliation><nlm:aff id="au3"><institution>Clinical Pharmacology Unit, SmithKline Beecham Pharmaceuticals</institution><addr-line>Harlow, Essex, CM19 5AW UK</addr-line></nlm:aff><wicri:noCountry code="subfield">CM19 5AW UK</wicri:noCountry></affiliation></author><author><name sortKey="Bullman, S" sort="Bullman, S" uniqKey="Bullman S" first="S" last="Bullman">S. Bullman</name><affiliation wicri:level="1"><nlm:aff id="au4"><institution>Drug Metabolism and Pharmacokinetics, SmithKline Beecham Pharmaceuticals</institution><addr-line>The Frythe, Welwyn, Herts, AL6 9AR, UK</addr-line></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>The Frythe, Welwyn, Herts, AL6 9AR</wicri:regionArea></affiliation></author><author><name sortKey="Citerone, D R" sort="Citerone, D R" uniqKey="Citerone D" first="D R" last="Citerone">D R Citerone</name><affiliation wicri:level="1"><nlm:aff id="au4"><institution>Drug Metabolism and Pharmacokinetics, SmithKline Beecham Pharmaceuticals</institution><addr-line>The Frythe, Welwyn, Herts, AL6 9AR, UK</addr-line></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>The Frythe, Welwyn, Herts, AL6 9AR</wicri:regionArea></affiliation></author><author><name sortKey="Taylor, A C" sort="Taylor, A C" uniqKey="Taylor A" first="A C" last="Taylor">A C Taylor</name><affiliation wicri:level="1"><nlm:aff id="au4"><institution>Drug Metabolism and Pharmacokinetics, SmithKline Beecham Pharmaceuticals</institution><addr-line>The Frythe, Welwyn, Herts, AL6 9AR, UK</addr-line></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>The Frythe, Welwyn, Herts, AL6 9AR</wicri:regionArea></affiliation></author><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J L" last="Montastruc">J L Montastruc</name><affiliation wicri:level="1"><nlm:aff id="au1"><institution>Service de Pharmacologie Médicale et Clinique, INSERM U 455 et U 317, Faculté de Medecine</institution><addr-line>37 allées Jules Guesde, 31073 Toulouse Cedex, France</addr-line></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>37 allées Jules Guesde, 31073 Toulouse Cedex</wicri:regionArea></affiliation></author><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name><affiliation wicri:level="1"><nlm:aff id="au1"><institution>Service de Pharmacologie Médicale et Clinique, INSERM U 455 et U 317, Faculté de Medecine</institution><addr-line>37 allées Jules Guesde, 31073 Toulouse Cedex, France</addr-line></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>37 allées Jules Guesde, 31073 Toulouse Cedex</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="au2"><institution>Centre d’Investigation Clinique, hôpital Purpan</institution><addr-line>place du Docteur Baylac, 31059 Toulouse Cedex, France</addr-line></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>place du Docteur Baylac, 31059 Toulouse Cedex</wicri:regionArea></affiliation></author></analytic><series><title level="j">British Journal of Clinical Pharmacology</title><idno type="ISSN">0306-5251</idno><idno type="eISSN">1365-2125</idno><imprint><date when="1998">1998</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Aims</title><p>Ropinirole is a specific non-ergoline dopamine D<sub>2</sub>-receptor agonist with antiparkinsonian properties. The pharmacokinetic parameters of ropinirole taken in the fasted condition were compared with those when it was co-administered with food.</p></sec><sec sec-type="methods"><title>Methods</title><p>This was an open, randomized, two sessions cross over study in 12 patients with Parkinson’s disease, comparing the steady-state pharmacokinetic profiles of ropinirole on two different study days: ‘fasted’ and ‘fed’.</p></sec><sec><title>Results</title><p>The mean <italic>C</italic><sub>max</sub> was lower in the ‘fed’ regimen than in the ‘fasted’ one (−25%, <italic>P</italic> = 0.002). The median <italic>t</italic><sub>max</sub> was observed 2.6 h later in the ‘fed’ regimen than in the ‘fasted’ regimen (<italic>P</italic><0.05). There was a slight but significant decrease in AUC(0,8 h) in the ‘fed’ regimen (<italic>P</italic> = 0.03).</p></sec><sec><title>Conclusions</title><p>Food decreases the rate of absorption of ropinirole, but has little effect on the extent of absorption.</p></sec></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Clin Pharmacol</journal-id><journal-id journal-id-type="publisher-id">bcp</journal-id><journal-title>British Journal of Clinical Pharmacology</journal-title><issn pub-type="ppub">0306-5251</issn><issn pub-type="epub">1365-2125</issn><publisher><publisher-name>Blackwell Science Inc</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">9578193</article-id><article-id pub-id-type="pmc">1873962</article-id><article-id pub-id-type="doi">10.1046/j.1365-2125.1998.t01-1-00704.x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Brefel</surname><given-names>C</given-names></name><xref rid="au1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Thalamas</surname><given-names>C</given-names></name><xref rid="au2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Rayet</surname><given-names>S</given-names></name><xref rid="au2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Lopez-Gil</surname><given-names>A</given-names></name><xref rid="au3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Fitzpatrick</surname><given-names>K</given-names></name><xref rid="au3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Bullman</surname><given-names>S</given-names></name><xref rid="au4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Citerone</surname><given-names>D R</given-names></name><xref rid="au4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Taylor</surname><given-names>A C</given-names></name><xref rid="au4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Montastruc</surname><given-names>J L</given-names></name><xref rid="au1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Rascol</surname><given-names>O</given-names></name><xref rid="au1" ref-type="aff">1</xref><xref rid="au2" ref-type="aff">2</xref></contrib><aff id="au1"><label>1</label><institution>Service de Pharmacologie Médicale et Clinique, INSERM U 455 et U 317, Faculté de Medecine</institution><addr-line>37 allées Jules Guesde, 31073 Toulouse Cedex, France</addr-line></aff><aff id="au2"><label>2</label><institution>Centre d’Investigation Clinique, hôpital Purpan</institution><addr-line>place du Docteur Baylac, 31059 Toulouse Cedex, France</addr-line></aff><aff id="au3"><label>3</label><institution>Clinical Pharmacology Unit, SmithKline Beecham Pharmaceuticals</institution><addr-line>Harlow, Essex, CM19 5AW UK</addr-line></aff><aff id="au4"><label>4</label><institution>Drug Metabolism and Pharmacokinetics, SmithKline Beecham Pharmaceuticals</institution><addr-line>The Frythe, Welwyn, Herts, AL6 9AR, UK</addr-line></aff></contrib-group><author-notes><corresp id="cor1">Correspondence: Professor O. Rascol, Service de Pharmacologie Médicale et Clinique, INSERM U 455, Faculté de Medecine, 37 allées Jules Guesde, 31073 Toulouse Cedex, France.</corresp></author-notes><pub-date pub-type="ppub"><month>4</month><year>1998</year></pub-date><volume>45</volume><issue>4</issue><fpage>412</fpage><lpage>415</lpage><history><date date-type="received"><day>07</day><month>4</month><year>1997</year></date><date date-type="accepted"><day>04</day><month>12</month><year>1997</year></date></history><copyright-statement>© 1998 Blackwell Science Ltd</copyright-statement><copyright-year>1998</copyright-year><abstract><sec><title>Aims</title><p>Ropinirole is a specific non-ergoline dopamine D<sub>2</sub>-receptor agonist with antiparkinsonian properties. The pharmacokinetic parameters of ropinirole taken in the fasted condition were compared with those when it was co-administered with food.</p></sec><sec sec-type="methods"><title>Methods</title><p>This was an open, randomized, two sessions cross over study in 12 patients with Parkinson’s disease, comparing the steady-state pharmacokinetic profiles of ropinirole on two different study days: ‘fasted’ and ‘fed’.</p></sec><sec><title>Results</title><p>The mean <italic>C</italic><sub>max</sub> was lower in the ‘fed’ regimen than in the ‘fasted’ one (−25%, <italic>P</italic> = 0.002). The median <italic>t</italic><sub>max</sub> was observed 2.6 h later in the ‘fed’ regimen than in the ‘fasted’ regimen (<italic>P</italic><0.05). There was a slight but significant decrease in AUC(0,8 h) in the ‘fed’ regimen (<italic>P</italic> = 0.03).</p></sec><sec><title>Conclusions</title><p>Food decreases the rate of absorption of ropinirole, but has little effect on the extent of absorption.</p></sec></abstract><kwd-group><kwd>dopaminergic agonist</kwd><kwd>ropinirole</kwd><kwd>pharmacokinetics</kwd><kwd>food interaction</kwd><kwd>Parkinson’s disease</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000428 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 000428 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Pmc
|étape= Curation
|type= RBID
|clé= PMC:1873962
|texte= Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:9578193" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |